Established in 1999, Suzhou Lixin Pharmaceutical Co., Ltd is dedicated in the manufacturing active pharmaceutical ingredients (APIs)and High-added-value intermediates. In pursuit of regulated API market in and out of China since its establishment, lixin has built GMP certificated workshops, Chemical Synthesis Workshops, facilities, and established standard quality management system and advanced quality control profile. Oriented at international market of APIs and intermediate materials, Lixin has built strong cooperation with domestic and international pharmaceutical companies. With the innovation of production process and patent protection, it already has series of APIs including anti-tumor drugs, cardiovascular drugs and so on.　In order to obtain favorable comments from customers on our high-quality products and standard quality management system, Lixin insists studying the process and product quality under the guidelines of ICH and the rules of SFDA. Lixin possesses a team of chemical scientists and managers engaged in the pharmaceutical industry for decades of years. They strive to make innovations in new products research, development, technology improvement, quality control, quality management, product sales and service, etc. Our featured products include: Hydrochlorothiazide(Biggest supplier in China, output 100mt/year, GMP certificated and USDMF available.), Indapamide(Biggest supplier in China, output 30mt/year, GMP certificated), Idebenone (Biggest supplier in China, output 20mt/year, GMP certificated), Dacarbazine(Biggest supplier in China, output 1mt/year, GMP certificated), Clopidogrel Bisulfate (Best supplier in China, with lowest impurity content). Meanwhile we have a series of anti-cancer APIs in development. Commercialized products include, Bumetanide, Pemetrexed Disodium, Oxaliplatin, Capecitabine, among others.